SCHEMBL5756441

SCHEMBL5756441

Oc1ccc2nc(-c3ccc(Cl)cc3O)sc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.61
KDM4E B2RXH2 2/20 0.61
NPC1 O15118 1/20 0.61
RAB9A P51151 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
GAA P10253 2/20 0.53
MGAM O43451 1/20 0.53
SI P14410 1/20 0.53
MGAM2 Q2M2H8 1/20 0.53
APP P05067 11/20 0.53
SULT1A1 P50225 3/20 0.52
HTT P42858 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA9 Q16790 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12471100 0.86 MGAM (0.70) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL7187329 0.83 MAPT (0.72) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL5754402 0.83 KDM4E (0.58) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL13806264 0.82 APP (0.68) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL27748200 0.82 MAPT (0.70) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL5416207 0.81 MAPT (0.69) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL5760456 0.79 MAPT (0.48) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL5756334 0.79 ILK (0.50) MAPTKDM4ENPC1RAB9ANPSR1
SCHEMBL4799750 0.78 APP (0.68) MAPTKDM4ENPC1RAB9AGAA
SCHEMBL5757037 0.77 CASP3 (0.46) MAPTKDM4ENPC1RAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1539723-B1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2006-05-24 EP claimed
US-20060106015-A1 Novel use of benzothiazole derivatives ASTRAZENECA (SE) 2006-05-18 US claimed
CN-1675189-A New use of benzothiazole derivatives ASTRAZENECA AB (SE) 2005-09-28 CN claimed
EP-1539723-B1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2006-05-24 EP disclosed
US-20060106015-A1 Novel use of benzothiazole derivatives ASTRAZENECA (SE) 2006-05-18 US disclosed
CN-1675189-A New use of benzothiazole derivatives ASTRAZENECA AB (SE) 2005-09-28 CN disclosed
EP-1539723-A1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES AstraZeneca AB (SE) 2005-06-15 EP disclosed
WO-2004016600-A1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2004-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106015-A1 Novel use of benzothiazole derivatives ITK, WEE2, WEE1 MAPT 3300/4885KDM4E 2318/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.